Kidney Outcomes in Long-Term Studies of Ruboxistaurin for Diabetic Eye Disease | Zendy

Katherine R. Tuttle | Zendy; Janet B. McGill | Zendy; Douglas J. Haney | Zendy; Toni E. Lin | Zendy; Pamela W. Anderson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Kidney Outcomes in Long-Term Studies of Ruboxistaurin for Diabetic Eye Disease

Author(s) -

Katherine R. Tuttle,

Janet B. McGill,

Douglas J. Haney,

Toni E. Lin,

Pamela W. Anderson

Publication year - 2007

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.00840207

Subject(s) - medicine , kidney disease , diabetic nephropathy , renal function , albuminuria , diabetic retinopathy , microalbuminuria , creatinine , urology , nephropathy , kidney , diabetes mellitus , placebo , gastroenterology , endocrinology , pathology , alternative medicine

A pilot study showed that ruboxistaurin (RBX), a protein kinase C beta inhibitor, significantly decreased albuminuria and stabilized kidney function over 1 yr in patients who had diabetic nephropathy and persistent macroalbuminuria despite receiving the current standard of care, including renin-angiotensin system inhibition. In contrast, in a trial of patients with diabetic retinopathy, investigators reported the adverse event "diabetic nephropathy" more frequently in patients who received RBX.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research